Moody National Bank Trust Division Has $6.09 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jul 3rd, 2023

Moody National Bank Trust Division raised its position in Pfizer Inc. (NYSE:PFE – Free Report) by 0.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 149,373 shares of the biopharmaceutical company’s stock after acquiring an additional 543 shares during the period. Pfizer comprises approximately 0.5% of Moody National Bank Trust Division’s holdings, making the stock its 27th largest holding. Moody National Bank Trust Division’s holdings in Pfizer were worth $6,094,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of PFE. Harbor Investment Advisory LLC grew its stake in shares of Pfizer by 3.6% in the 4th quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock valued at $1,229,000 after purchasing an additional 825 shares during the period. BancFirst Trust & Investment Management boosted its stake in Pfizer by 2.3% in the 1st quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 398 shares in the last quarter. Secure Asset Management LLC grew its position in Pfizer by 3.5% in the fourth quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock valued at $811,000 after acquiring an additional 537 shares during the period. Range Financial Group LLC raised its stake in Pfizer by 2.8% during the first quarter. Range Financial Group LLC now owns 37,010 shares of the biopharmaceutical company’s stock worth $1,510,000 after acquiring an additional 1,024 shares in the last quarter. Finally, Allred Capital Management LLC lifted its holdings in shares of Pfizer by 1.9% during the fourth quarter. Allred Capital Management LLC now owns 20,425 shares of the biopharmaceutical company’s stock valued at $1,047,000 after acquiring an additional 387 shares during the period. Institutional investors own 67.80% of the company’s stock.

Pfizer Stock Up 1.6 %

Shares of NYSE:PFE opened at $36.68 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.37 and a quick ratio of 1.11. The stock has a market cap of $207.07 billion, a price-to-earnings ratio of 7.22, a P/E/G ratio of 1.22 and a beta of 0.61. The company has a 50 day moving average of $38.32 and a 200-day moving average of $42.05. Pfizer Inc. has a one year low of $35.76 and a one year high of $54.93.

Pfizer (NYSE:PFE – Free Report) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.23. The firm had revenue of $18.28 billion during the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The business’s quarterly revenue was down 28.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.62 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 3.35 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be paid a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 4.47%. The ex-dividend date of this dividend is Thursday, July 27th. Pfizer’s payout ratio is 32.28%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on PFE shares. Barclays dropped their target price on shares of Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. Daiwa Capital Markets cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 target price for the company. in a research note on Thursday, May 11th. UBS Group dropped their price target on Pfizer from $41.00 to $39.00 in a report on Friday, May 5th. Bank of America reduced their price objective on Pfizer from $50.00 to $45.00 and set a “neutral” rating on the stock in a research note on Friday, April 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Pfizer in a report on Wednesday, May 17th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $46.67.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction that occurred on Monday, May 8th. The shares were acquired at an average cost of $38.58 per share, for a total transaction of $38,580.00. Following the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $231,480. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.05% of the company’s stock.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.